0000846475 false 0000846475 2021-04-29 2021-04-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares




Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 29, 2021


Zynex, Inc.

(Exact Name of Registrant as Specified in its Charter)


       Nevada        001-38804 90-0275169
(State or other jurisdiction
 of incorporation)
Commission File

(I.R.S. Employer Identification



9555 Maroon Circle, Englewood, CO 80112

(Address of principal executive offices)  (Zip Code)


Registrant's telephone number, including area code:  (303) 703-4906


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Ticker symbol(s) Name of each exchange on which
Common Stock, $0.001 par value per share ZYXI The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







ITEM 2.02 Results of Operations and Financial Condition


On April 29, 2021, Zynex, Inc. issued a press release announcing certain results for the first quarter of 2021. The full text of the press release is furnished herewith as Exhibit 99.1.


The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.




d)         Exhibits. The following exhibits are filed with this report.


Exhibit No.  Description
99.1  Zynex, Inc. Press Release dated April 29, 2021







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Dated: April 29, 2021 ZYNEX, INC.
  /s/ Dan Moorhead
  Dan Moorhead
  Chief Financial Officer




EX-99.1 2 tm2114550d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1


Zynex Announces 2021 First Quarter Earnings


·2021 First Quarter


oRevenue increased 58% year over year to $24.1 million


oOrders increased 140%


oNet loss of $0.7 million; GAAP loss per share $0.02


oAdjusted EBITDA loss $0.4 million


ENGLEWOOD, CO – April 29, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its first quarter ended March 31, 2021.


First Quarter Financial Results Summary:


For the first quarter, the Company reported net revenue of $24.1 million, a 58% increase over the first quarter of 2020. Gross margins were 76% in the first quarter of 2021 and net loss was $0.7 million.


There was an Adjusted EBITDA loss of $0.4 million in the first quarter of 2021.


As of March 31, 2021, the company had working capital of $51.5 million. Cash on hand was $33.4 million at the end of the first quarter. Cash decreased during the quarter due to the company maintaining higher than normal inventory levels to protect against any supplier delays related to COVID-19. There have not been any issues with supplier deliveries to date.


President and CEO Commentary:


Thomas Sandgaard, CEO said: “I am excited about our order growth in the first quarter of 140% which will continue to drive increasing revenue throughout 2021 and 2022. In the first quarter, we posted revenue of $24.1 million. First quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year. The combination of seasonality of deductibles along with the sales force investments we made during 2020 produced a small loss in Q1 which was expected. Profitability is expected to ramp quickly beginning in second quarter with projected Adjusted EBITDA of over $3 million.


In the first quarter, we focused on productivity of our existing sales reps and trimmed our sales force slightly below 500. We still expect to have over 600 sales reps by the end of 2021 with most of those additions coming in the second half of the year.


We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids.”


Second Quarter and Full Year 2021 Guidance:


The estimated range for second quarter revenue is between $31.0 and $32.5 million with Adjusted EBITDA between $3.0 and $4.0 million. The revenue estimate is approximately 61% to 69% above 2020 second quarter revenue of $19.3 million.


Full year 2021 revenue is estimated between $135.0 and $150.0 million with Adjusted EBITDA between $15.0 and $25.0 million. The full year revenue estimate is approximately 68% to 87% above 2020 revenue of $80.1 million. We expect profitability to continually ramp throughout the year to meet our Adjusted EBITDA forecast of $15 to $25 million for 2021.





Conference Call and Webcast Details:


Thursday, April 29, 2021 at 2:15 p.m. MT / 4:15 p.m. ET


To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:




Canada Toll Free: 1-855-669-9657


Non-GAAP Financial Measures


Zynex reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, other income/expense and stock compensation). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with GAAP.


About Zynex, Inc. 


Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.


Safe Harbor Statement


This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.


Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.


Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


Contact: Zynex, Inc. (800) 495-6670


Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel










   March 31,   December 31, 
   2021   2020 
Current assets:          
Cash  $33,439   $39,173 
Accounts receivable, net   14,874    13,837 
Inventory, net   10,957    8,635 
Prepaid expenses and other   1,559    1,378 
                                               Total current assets   60,829    63,023 
Property and equipment, net   2,299    1,925 
Operating lease asset   5,380    5,993 
Finance lease asset   457    321 
Deposits   340    347 
Deferred income taxes   931    566 
                                               Total assets  $70,236   $72,175 
Current liabilities:          
Accounts payable and accrued expenses   3,338    4,717 
Operating lease liability   2,043    2,051 
Finance lease liability   104    77 
Income taxes payable   266    280 
Accrued payroll and related taxes   3,564    2,992 
                                              Total current liabilities   9,315    10,117 
Long-term liabilities:          
Operating lease liability   4,371    4,920 
Finance lease liability   397    283 
                                              Total liabilities   14,083    15,320 
Stockholders' equity:          
Preferred stock   -    - 
Common stock   37    36 
Additional paid-in capital   37,313    37,235 
Treasury stock   (3,921)   (3,846)
Retained earnings   22,724    23,430 
                                              Total stockholders' equity   56,153    56,855 
                                              Total liabilities and stockholders' equity  $70,236   $72,175 







(in thousands, except per share data)


   For the Three Months Ended March 31, 
   2021   2020 
NET REVENUE          
Devices  $6,365   $3,444 
Supplies   17,762    11,784 
Total net revenue   24,127    15,228 
Costs of revenue - devices and supplies   5,886    3,401 
Sales and marketing   13,827    5,584 
General and administrative   5,495    3,785 
Total costs of revenue and operating expenses   25,208    12,770 
Income/(loss) from operations   (1,081)   2,458 
Other expense          
   Interest expense   (9)   (4)
Other expense, net   (9)   (4)
Income/(loss) from operations before income taxes   (1,090)   2,454 
  Income tax benefit   (384)   (483)
Net income/(loss)  $(706)  $2,937 
Net income/(loss) per share:          
Basic  $(0.02)  $0.09 
Diluted  $(0.02)  $0.09 
Weighted average basic shares outstanding   34,837    32,913 
Weighted average diluted shares outstanding   34,837    34,204 






Reconciliation of GAAP to Non-GAAP Measures

(in thousands)



   For the Three Months Ended March 31, 
   2021   2020 
Adjusted EBITDA:          
Net income  $(706)  $2,937 
Depreciation and Amortization*   268    68 
Stock-based compensation expense   108    497 
Restructuring/severance**   318    - 
Interest expense and other, net   9    4 
Income tax expense   (384)   (483)
Adjusted EBITDA  $(387)  $3,023 
% of Net Revenue   (2%)   20%


* Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold.

** Severance of former COO Giuseppe Papandrea which was fully expensed in Q1-2021




EX-101.SCH 3 zyxi-20210429.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zyxi-20210429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 zyxi-20210429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2114550d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000846475 2021-04-29 2021-04-29 iso4217:USD shares iso4217:USD shares 0000846475 false 8-K 2021-04-29 Zynex, Inc. NV 001-38804 90-0275169 9555 Maroon Circle Englewood CO 80112 303 703-4906 false false false false Common Stock, $0.001 par value per share ZYXI NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Apr. 29, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 29, 2021
Entity File Number 001-38804
Entity Registrant Name Zynex, Inc.
Entity Central Index Key 0000846475
Entity Tax Identification Number 90-0275169
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9555 Maroon Circle
Entity Address, City or Town Englewood
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80112
City Area Code 303
Local Phone Number 703-4906
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol ZYXI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://zynexmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2114550d1_8k.htm tm2114550d1_ex99-1.htm zyxi-20210429.xsd zyxi-20210429_lab.xml zyxi-20210429_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2114550d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2114550d1_8k.htm" ] }, "labelLink": { "local": [ "zyxi-20210429_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "zyxi-20210429_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "zyxi-20210429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zyxi", "nsuri": "http://zynexmed.com/20210429", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2114550d1_8k.htm", "contextRef": "From2021-04-29to2021-04-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://zynexmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2114550d1_8k.htm", "contextRef": "From2021-04-29to2021-04-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-057532-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-057532-xbrl.zip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end